New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
05:37 EDTRHHBY, NVSNovartis, Roche fined by Italy for alleged collusion on drug sale, WSJ reports
In Italy, the competition authority fined Roche Holding (RHHBY) and Novartis (NVS) for having allegedly colluded to exclude the sale of a cheap drug used for serious sight problems, reports the Wall Street Journal. Novartis was fined EUR 92M and Roche EUR 90.5M. Reference Link
News For NVS;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
06:36 EDTRHHBYImmunoGen: enrollment in expansion cohort for IMGN853 to complete by year end
Subscribe for More Information
July 30, 2015
09:25 EDTRHHBYLeerink life science tools analyst holds an analyst/industry conference call
Life Science Tools & Diagnostics Analyst Leonard, along with Dr. Anami Patel and Dr. Nathan Ledeboer, discuss their perspectives on Point-of-Care molecular tests including the opportunity in virology / microbiology, the threat to traditional lab-based testing and point-of-care instruments on an Analyst/Industry conference call to be held on July 30 at 11 am.
05:57 EDTRHHBYRoche submits filing to FDA for companion diagnostic for NSCLC drug therapy
Roche announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval, or PMA, to the FDA, as a companion diagnostic test for AZD9291, an AstraZeneca (AZN) investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation. Patients with non-small cell lung cancer who have adenocarcinoma with tumor containing an EGFR sensitizing mutation show significant benefit from currently available EGFR TKI therapies. However, approximately two-thirds of these patients will relapse and develop drug resistance. In many cases, this resistance is caused by an acquired mutation called T790M. The cobas EGFR v2 test can aid clinicians to appropriately select NSCLC patients who have acquired the T790M mutation and are most likely to benefit from AstraZeneca's novel therapy.
July 29, 2015
05:28 EDTNVSNovartis announces equity stake in Mereo BioPharma Group
Novartis announced a swap of clinical assets for equity with Mereo BioPharma Group. The deal involves compounds in areas of unmet medical need including BPS-804, to improve bone density in brittle bone syndrome, an orphan disease; BCT-197 for acute exacerbations in COPD, and BGS-649 for obese men with hypogonadotrophic hypogonadism to normalize testosterone levels. Under the terms of the agreement, Novartis will have an equity stake in Mereo and will share in the success of the development of these compounds, including a share on milestones and royalties on future commercial sales.
July 28, 2015
07:08 EDTRHHBYRoche introduced several diagnostic testing platforms at the AACC 2015
Subscribe for More Information
July 24, 2015
10:56 EDTNVSNovartis announces FDA approval of Odomzo
Subscribe for More Information
09:02 EDTNVSLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information
07:17 EDTNVSNovartis combination therapy Tafinlar, Mekinist achieves regulatory milestones
Subscribe for More Information
July 23, 2015
06:27 EDTRHHBYRoche CEO expects biosimilars in Europe by late 2017, Reuters reports
Subscribe for More Information
05:46 EDTRHHBYRoche expects FY15 sales to grow low- mid-single digits
Expects FY15 core EPS to grow ahead of sales at constant exchange rates. Roche expects to further increase dividend in Swiss francs.
05:45 EDTRHHBYRoche reports 1H15 core EPS CHF 7.22 vs. 7.57 last year
Subscribe for More Information
July 22, 2015
07:03 EDTNVSIgnyta names Bernard Parker as Chief Commercial Officer
Subscribe for More Information
July 21, 2015
11:49 EDTNVSNovartis may sell Amgen's cancer drug as soon as September, Bloomberg says
Subscribe for More Information
07:05 EDTRHHBYOphthotech names Shima as Chief Scientific Officer, Bjarke as CCO
Subscribe for More Information
05:20 EDTNVSNovartis backs FY15 revenue guidance of up mid-single digit
Subscribe for More Information
05:17 EDTNVSNovartis reports Q2 core EPS $1.27, consensus $1.24
Reports Q2 revenue $12.7B, consensus $12.44B. Further strengthening of USD impacted sales by -11% and core operating income by -13%. Growth Products, an indicator of the rejuvenation of the portfolio, contributed 35% of continuing operations net sales in Q2, and were up 24%. In Pharmaceuticals, Growth Products contributed 44% of division net sales in the quarter, and sales for these products were up 38%.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use